## Atsuko Kamijo-Ikemori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2771258/publications.pdf

Version: 2024-02-01

39 papers 1,027 citations

16 h-index 31 g-index

39 all docs 39 docs citations

39 times ranked 1001 citing authors

#	Article	IF	CITATIONS
1	Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients. Diabetes Care, 2011, 34, 691-696.	8.6	126
2	Usefulness of Urinary Biomarkers in Early Detection of Acute Kidney Injury After Cardiac Surgery in Adults. Circulation Journal, 2012, 76, 213-220.	1.6	88
3	Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial Damage. American Journal of Pathology, 2009, 174, 2096-2106.	3.8	87
4	Urinary fatty acid binding protein in renal disease. Clinica Chimica Acta, 2006, 374, 1-7.	1.1	79
5	Liver-Type Fatty Acid-Binding Protein Attenuates Renal Injury Induced by Unilateral Ureteral Obstruction. American Journal of Pathology, 2006, 169, 1107-1117.	3 <b>.</b> 8	72
6	Urinary liver type fatty acid binding protein in diabetic nephropathy. Clinica Chimica Acta, 2013, 424, 104-108.	1.1	60
7	Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy. Nephron Clinical Practice, 2009, 112, c148-c156.	2.3	52
8	Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clinical and Experimental Nephrology, 2011, 15, 220-225.	1.6	43
9	Amelioration of diabetic tubulointerstitial damage in liver-type fattyÂacid-binding protein transgenic mice. Nephrology Dialysis Transplantation, 2009, 24, 788-800.	0.7	38
10	Roles of human liver type fatty acid binding protein in kidney disease clarified using hLâ€FABP chromosomal transgenic mice. Nephrology, 2011, 16, 539-544.	1.6	38
11	Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clinical and Experimental Nephrology, 2016, 20, 195-203.	1.6	37
12	Novel Urinary Biomarkers in Early Diabetic Kidney Disease. Current Diabetes Reports, 2014, 14, 513.	4.2	28
13	Renal Liver-Type Fatty Acid Binding Protein Attenuates Angiotensin II–Induced Renal Injury. Hypertension, 2012, 60, 973-980.	2.7	27
14	Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair. Journal of Anesthesia, 2016, 30, 89-99.	1.7	25
15	Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury. American Journal of Physiology - Renal Physiology, 2016, 310, F1366-F1376.	2.7	22
16	Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone-and salt-induced renal injury. Hypertension Research, 2018, 41, 8-17.	2.7	21
17	Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats. Clinical and Experimental Nephrology, 2021, 25, 365-375.	1.6	16
18	Human liver-type fatty acid–binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury. American Journal of Physiology - Renal Physiology, 2015, 308, F114-F121.	2.7	14

#	Article	IF	Citations
19	Distinct Roles of Urinary Liver-Type Fatty Acid-Binding Protein in Non-Diabetic Patients with Anemia. PLoS ONE, 2015, 10, e0126990.	2.5	13
20	Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals. Clinical and Experimental Nephrology, 2017, 21, 810-817.	1.6	13
21	Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation. American Journal of Physiology - Renal Physiology, 2014, 306, F655-F663.	2.7	12
22	Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression. European Journal of Pharmacology, 2017, 815, 88-97.	3.5	11
23	Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia–reperfusion. Nephrology, 2018, 23, 308-316.	1.6	11
24	Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 1716-1729.	2.0	11
25	Increase in urinary markers during the acute phase reflects the degree of chronic tubulointerstitial injury after ischemia-reperfusion renal injury. Biomarkers, 2017, 22, 5-13.	1.9	9
26	Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Renal Replacement Therapy, $2017, 3, .$	0.7	9
27	The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats. Kidney and Blood Pressure Research, 2019, 44, 1476-1492.	2.0	8
28	Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats. Journal of Diabetes Research, 2020, 2020, 1-14.	2.3	8
29	Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice. Hypertension Research, 2019, 42, 1518-1527.	2.7	6
30	Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Molecular and Cellular Endocrinology, 2022, 539, 111472.	3.2	6
31	Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1645-1654.	2.3	5
32	Association between muscular strength and intrarenal vascular resistance in middle-aged and older individuals. Experimental Gerontology, 2017, 91, 72-78.	2.8	5
33	Incremental short maximal exercise increases urinary liverâ€type fatty acidâ€binding protein in adults without CKD. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 709-715.	2.9	5
34	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate–salt hypertension. FASEB Journal, 2017, 31, 72-84.	0.5	4
35	Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion. Scientific Reports, 2021, 11, 982.	3.3	4
36	Endurance Exercise Training-Attenuated Diabetic Kidney Disease with Muscle Weakness in Spontaneously Diabetic Torii Fatty Rats. Kidney and Blood Pressure Research, 2022, 47, 203-218.	2.0	4

#	Article	IF	CITATIONS
37	Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats. BMC Ophthalmology, 2022, 22, 206.	1.4	4
38	Clinical Utility of Urinary Biomarkers for Prediction of Acute Kidney Injury and Chronic Renal Dysfunction After Open Abdominal Aortic Aneurysm Repair. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 371-384.	1.8	3
39	Quantitative and qualitative analyses of urinary L-FABP for predicting acute kidney injury after emergency laparotomy. Journal of Anesthesia, $2021$ , , $1$ .	1.7	3